Non-peptidyl insulin mimetics as a potential antidiabetic agent

Drug Discovery Today

Volumn 18, Issue 15-16, 2013, Pages 748-755

  Nankar, Rakesh P ^a   Doble, Mukesh ^a  

^a INDIAN INSTITUTE OF TECHNOLOGY MADRAS   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; BENZOQUINONE DERIVATIVE; ERTIPROTAFIB; GLUCOSE; INSULIN DERIVATIVE; INSULIN RECEPTOR; ISIS 113715; NON RECEPTOR PROTEIN TYROSINE PHOSPHATASE 2; NORASTERRIQUINONE B1; ORGANIC COMPOUND; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE PHOSPHATASE 1B; VANADIC ACID; VANADIUM DERIVATIVE; VANADYL SULFATE;

ANTIDIABETIC ACTIVITY; AUTOPHOSPHORYLATION; BINDING SITE; BIOMIMETICS; CLINICAL TRIAL (TOPIC); DIABETES MELLITUS; DRUG BIOAVAILABILITY; DRUG MECHANISM; DRUG POTENCY; DRUG SPECIFICITY; ENZYME INHIBITION; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; GLUCOSE TRANSPORT; HUMAN; HYPERGLYCEMIA; INSULIN RESISTANCE; INSULIN SENSITIVITY; INSULIN TREATMENT; NONHUMAN; REVIEW; STRUCTURE ACTIVITY RELATION; UNSPECIFIED SIDE EFFECT;

ANIMALS; BIOMIMETIC MATERIALS; BIOMIMETICS; DIABETES MELLITUS; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84881137971     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2013.04.005     Document Type: Review

References (60)

1. American Diabetes Association Diagnosis and Classification of Diabetes Mellitus Diabetes Care 34 Suppl. 1 2011 S62 S69
2. M.L. Mohler Recent and emerging anti diabetes targets Med. Res. Rev. 29 2009 125 195
3. L.G. Hemkens Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study Diabetologia 52 2009 1732 1744
4. M.H. Shanik Insulin resistance and hyperinsulinemia: is hyperinsulinemia the cart or the horse? Diabetes Care 31 Suppl. 2 2008 S262 S268
5. D. Le Roith, and Y. Zick Recent advances in our understanding of insulin action and insulin resistance Diabetes Care 24 2001 588 597 (Pubitemid 32198431)
6. K. Cusi Insulin resistance differentially affects the PI 3-kinase-and MAP kinase-mediated signaling in human muscle J. Clin. Invest. 105 2000 311 320 (Pubitemid 30094451)
7. J.W. Leef, and J. Larner Insulin-mimetic effect of trypsin on the insulin receptor tyrosine kinase in intact adipocytes J. Biol. Chem. 262 1987 14837 14842
8. G.M. Salituro Discovery of a small molecule insulin receptor activator Recent Prog. Horm. Res. 56 2001 107 126
9. B. Zhang Discovery of a small molecule insulin mimetic with antidiabetic activity in mice Science 284 1999 974 977 (Pubitemid 29288438)
10. N.J.G. Webster Signaling effects of demethylasterriquinone B1, a selective insulin receptor modulator Chembiochem 4 2003 379 385 (Pubitemid 36604322)
11. M.A. Weber A novel insulin mimetic without a proliferative effect on vascular smooth muscle cells J. Vasc. Surg. 32 2000 1118 1126
12. 2+] and insulin secretion from pancreatic β-cells Diabetes 51 Suppl. 1 2002 S43 S49
13. E.L. Air Small molecule insulin mimetics reduce food intake and body weight and prevent development of obesity Nat. Med. 8 2002 179 183 (Pubitemid 34155130)
14. K. Liu Discovery of a potent, highly selective, and orally efficacious small-molecule activator of the insulin receptor J. Med. Chem. 43 2000 3487 3494
15. V.D.H. Ding Regulation of insulin signal transduction pathway by a small-molecule insulin receptor activator Biochem. J. 367 2002 301 306 (Pubitemid 35176919)
16. M.C. Pirrung Synthesis of 2,5-dihydroxy-3-(indol-3-yl)benzoquinones by acid-catalysed condensation of indoles with 2,5-dichlorobenzoquinone J. Org. Chem. 67 2002 8374 8388 (Pubitemid 35402983)
17. B. Lin Identification of novel orally available small molecule insulin mimetics J. Pharmacol. Exp. Ther. 323 2007 579 585 (Pubitemid 350005119)
18. J. Koyama Anti-infective quinone derivatives of recent patents Recent Pat. Anti-infect. Drug Discov. 1 2006 113 125
19. J.I. Aguilo Cytotoxicity of quinone drugs on highly proliferative human leukemia T cells: reactive oxygen species generation and inactive shortened SOD1 isoform implications Chem. Biol. Interact. 198 2012 18 28
20. Chen, S.S.T. et al. Antidiabetic 4-hydroxy-2-furoic acids. Merck and Co. Inc., Rahway, NJ (US). USP 6,596,760 B1
21. H.J. Tsai, and S.Y. Chou A novel hydroxyfuroic acid compound as an insulin receptor activator. Structure and activity relationship of a prenylindole moiety to insulin receptor activation J. Biomed. Sci. 16 2009 68
22. S. Belmadani Elevated epidermal growth factor receptor phosphorylation induces resistance artery dysfunction in diabetic db/db mice Diabetes 57 2008 1629 1637
23. A. Beenken, and M. Mohammadi The FGF family: biology, pathophysiology and therapy Nat. Rev. Drug Discov. 8 2009 235 253
24. Pirrung, M.C. Small molecule insulin mimetic absent quinones. USP 2011/0028519A1
25. P.K. Prabhakar, and M. Doble A target based therapeutic approach towards diabetes mellitus using medicinal plants Curr. Diabetes Rev. 4 2008 291 308
26. B. Diesel α-Lipoic acid as a directly binding activator of the insulin receptor: protection from hepatocyte apoptosis Biochemistry 46 2007 2146 2155 (Pubitemid 46355324)
27. Y.K. Rao Insulin-mimetic action of rhoifolin and cosmosiin isolated from Citrus grandis (L.) Osbeck leaves: enhanced adiponectin secretion and insulin receptor phosphorylation in 3T3-L1 cells Evidence-Based Complement. Alternat. Med. 2011 2009 1 9
28. X. Liu Tannic acid stimulates glucose transport and inhibits adipocyte differentiation in 3T3-L1 cells J. Nutr. 135 2005 165 171 (Pubitemid 40194473)
29. K. Hattori Activation of insulin receptors by lagerstroemin J. Pharmacol. Sci. 93 2003 69 73 (Pubitemid 37254269)
30. S.H. Jung Insulin-mimetic and insulin-sensitizing activities of a pentacyclic triterpenoid insulin receptor activator Biochem. J. 403 Pt 2 2007 243 250 (Pubitemid 46596579)
31. K.H. Thompson Vanadium compounds as insulin mimics Chem. Rev. 99 1999 2561 2572
32. N. Wiernsperger, and J. Rapin Trace elements in glucometabolic disorders: an update Diabetol. Metab. Syndr. 19 2010 70
33. Y. Shechter Historic perspective and recent developments on the insulin-like actions of vanadium; toward developing vanadium-based drugs for diabetes Coord. Chem. Rev. 237 2003 3 11
34. J. Meyerovitch Oral administration of vanadate normalizes blood glucose levels in streptozotocin-treated rats. Characterization and mode of action J. Biol. Chem. 262 1987 6658 6662 (Pubitemid 17104143)
35. S.M. Brichard Long term improvement of glucose homeostasis by vanadate in obese hyperinsulinemic fa/fa rats Endocrinology 125 1989 2510 2516 (Pubitemid 19279438)
36. J. Meyerovitch Vanadate normalizes hyperglycemia in two mouse models of non-insulin-dependent diabetes mellitus J. Clin. Invest. 87 1991 1286 1294
37. K. Cusi Vanadyl sulfate improves hepatic and muscle insulin sensitivity in type 2 diabetes J. Clin. Endocrinol. Metab. 86 2001 1410 1417 (Pubitemid 32323036)
38. G. Huyer Mechanism of inhibition of protein-tyrosine phosphatases by vanadate and pervanadate J. Biol. Chem. 272 1997 843 851 (Pubitemid 27034572)
39. A. Shisheva, and Y. Shechter Role of cytosolic tyrosine kinase in mediating insulin-like actions of vanadate in rat adipocytes J. Biol. Chem. 268 1993 6463 6469 (Pubitemid 23099344)
40. G. Elberg Vanadate activates membranous nonreceptor protein tyrosine kinase in rat adipocytes Diabetes 46 1997 1684 1690 (Pubitemid 27456398)
41. B.I. Posner Peroxovanadium compounds. A new class of potent phosphotyrosine phosphatase inhibitors which are insulin mimetics J. Biol. Chem. 269 1994 4596 4604
42. S. Zhang, and Z.Y. Zhang PTP1B as a drug target: recent developments in PTP1B inhibitor discovery Drug Discov. Today 12 2007 373 381 (Pubitemid 46636379)
43. Z.Y. Zhang Protein tyrosine phosphatases: structure and function, substrate specificity, and inhibitor development Annu. Rev. Pharmacol. Toxicol. 42 2002 209 234
44. L. Bialy, and H. Waldmann Inhibitors of protein tyrosine phosphatases: next generation drugs? Angew. Chem. Int. Ed. 44 2005 3814 3839 (Pubitemid 40885689)
45. Y.A. Puius Identification of a second aryl phosphate-binding site in protein-tyrosine phosphatase 1B: a paradigm for inhibitor design Proc. Natl. Acad. Sci. U.S.A. 94 1997 13420 13425
46. K. Shen Acquisition of a specific and potent PTP1B inhibitor from a novel combinatorial library and screening procedure J. Biol. Chem. 276 2001 47311 47319
47. C.K. Lau Structure based design of a series of potent and selective non peptidic PTP-1B inhibitors Bioorg. Med. Chem. Lett. 14 2004 1043 1048 (Pubitemid 38167639)
48. M. Sarmiento Molecular basis for substrate specificity of protein-tyrosine phosphatase 1B J. Biol. Chem. 273 1998 26368 26374 (Pubitemid 28471640)
49. G. Liu Selective protein tyrosine phosphatase 1B inhibitors: targeting the second phosphotyrosine binding site with non-carboxylic acid-containing ligands J. Med. Chem. 46 2003 3437 3440 (Pubitemid 36909816)
50. D.P. Wilson Structure-based optimization of protein tyrosine phosphatase 1B inhibitors: from the active site to the second phosphotyrosine binding site J. Med. Chem. 50 2007 4681 4698 (Pubitemid 47463242)
51. C. Liljebris Synthesis and biological activity of a novel class of pyridazine analogues as non-competitive reversible inhibitors of protein tyrosine phosphatase 1B (PTP1B) Bioorg. Med. Chem. 10 2002 3197 3212 (Pubitemid 34855393)
52. C. Wiesmann Allosteric inhibition of protein tyrosine phosphatase 1B Nat. Struct. Mol. Biol. 11 2004 730 737 (Pubitemid 39014498)
53. J. Wrobel PTP1B inhibition and antihyperglycemic activity in the ob/ob mouse model of novel 11-arylbenzo [b] naphtho [2,3-d] furans and 11-arylbenzo [b] naphtho [2,3-d] thiophenes J. Med. Chem. 42 1999 3199 3202 (Pubitemid 29409708)
54. D.V. Erbe Ertiprotafib improves glycemic control and lowers lipids via multiple mechanisms Mol. Pharmacol. 67 2005 69 77 (Pubitemid 40069967)
55. S. Shrestha PTP1B inhibitor Ertiprotafib is also a potent inhibitor of IκB kinase β (IKK-β) Bioorg. Med. Chem. Lett. 17 2007 2728 2730 (Pubitemid 46636263)
56. M. Stuible PTP1B and TC-PTP: regulators of transformation and tumorigenesis Cancer Metastasis Rev. 27 2008 215 230
57. K.E. You-Ten Impaired bone marrow microenvironment and immune function in T cell protein tyrosine phosphatase-deficient mice J. Exp. Med. 186 1997 683 693 (Pubitemid 27381533)
58. E. Asante-Appiah Conformation-assisted inhibition of protein-tyrosine phosphatase-1B elicits inhibitor selectivity over T-cell protein-tyrosine phosphatase J. Biol. Chem. 281 2006 8010 8015 (Pubitemid 43847418)
59. B.A. Zinker PTP1B antisense oligonucleotide lowers PTP1B protein, normalizes blood glucose, and improves insulin sensitivity in diabetic mice Proc. Natl. Acad. Sci. U.S.A. 99 2002 11357 11362 (Pubitemid 34920930)
60. M.M. Swarbrick Inhibition of protein tyrosine phosphatase-1B with antisense oligonucleotides improves insulin sensitivity and increases adiponectin concentrations in monkeys Endocrinology 150 2009 1670 1679